Login to Your Account



EORTC Roundup


Monday, November 12, 2012
• GenSpera Inc., of San Antonio, presented interim data from its ongoing Phase I trial of G-202 in patients with advanced solid tumor cancers. The main conclusions are that G-202 appeared to be well tolerated when administered via the recommended dosing regimen and that it should be evaluated in Phase II studies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription